A Peptide Meets a Radionuclide to Combat a Rare Tumor
Background: Neuroendocrine carcinomas (NECs) are rare malignancies with limited treatment options beyond surgery. Peptide receptor radionuclide therapy (PRRT) is a process by which a somatostatin analog (octreotate) is combined with a chelator (DOTA) and a radionuclide (lutetium-177 [177 Lu-dotatate]). This therapy targets receptors on neuroendocrine cells, causing internalization of the radionuclide by the tumor cell, which results in cellular damage and apoptosis. Case Report: We describe the clinical and therapeutic course of a 69-year-old male with a metastatic rectal NEC in whom progres-sive disease was noted after multiple therapies were attempted. After PRRT with177 Lu-dotatate, the patient was asymptomatic and demonstrated a near-complete radiologic response. Conclusion: This case illustrates that treatment with PRRT may improve the outcome of patients with metastatic rectal NEC. Our case highlights the importance of further research into the use of PRRT in patients with a Ki-67 <55% and uptake on somatostatin receptor imaging.
Thomas, Katharine E.; Boudreaux, J. Philip; Thiagarajan, Ramcharan; Marsala, Andrew; Voros, Brianne A.; and Ramirez, Robert A., "A Peptide Meets a Radionuclide to Combat a Rare Tumor" (2021). School of Medicine Faculty Publications. 400.